Todos Med (OTCMKTS:TOMDF) & Labcorp (NYSE:LH) Head-To-Head Review

Labcorp (NYSE:LH) and Todos Med (OTCMKTS:TOMDF) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Risk and Volatility

Labcorp has a beta of 0.99, indicating that its stock price is 1% less volatile than the S&P 500. Comparatively, Todos Med has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.

Valuation & Earnings

This table compares Labcorp and Todos Med”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Labcorp	$13.01 billion	1.61	$746.00 million	$10.18	24.76
Todos Med	N/A	N/A	N/A	N/A	N/A

Labcorp has higher revenue and earnings than Todos Med.

Profitability

This table compares Labcorp and Todos Med’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Labcorp	6.21%	15.85%	7.35%
Todos Med	N/A	N/A	N/A

Insider and Institutional Ownership

95.9% of Labcorp shares are held by institutional investors. 0.8% of Labcorp shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Labcorp and Todos Med, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Labcorp	0	4	11	0	2.73
Todos Med	0	0	0	0	0.00

Labcorp presently has a consensus target price of $299.08, suggesting a potential upside of 18.65%. Given Labcorp’s stronger consensus rating and higher probable upside, equities analysts plainly believe Labcorp is more favorable than Todos Med.

Summary

Labcorp beats Todos Med on 10 of the 10 factors compared between the two stocks.

About Labcorp

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.